Drug Discovery & Molecular Design - software & AI news

Daily news on software, AI, and companies shaping drug discovery & molecular design.

Showing 229 results
A minimalist illustration of a pill in a dark setting.

Jun 27, 2026

AI Drug Discovery Reaches Clinical Proof at BIO 2026: China Beat the BIOSECURE Act to Science

The BIO International Convention in San Diego recently highlighted significant advancements in AI drug discovery, marking a pivotal moment for the biopharma industry. Notably, generative AI has transitioned from theoretical discussions to producing tangible clinical results, demonstrating its potential to revolutionize drug development.At BIO 2026, the conversation shifted from skepticism about AI's capabilities to a focus on what is currently effective in drug design and the urgency of rapid de
Minimalist illustration of a T-cell and drug compound in a biotech context.

Jun 25, 2026

Israeli-founded AI biotech Immunai launches drug-discovery collaboration with Boehringer Ingelheim

Immunai, an Israeli-founded AI biotech firm, has initiated a collaboration with Boehringer Ingelheim, focusing on drug discovery for T-cell targets in immuno-oncology and autoimmune diseases. This partnership, valued at up to $15 million and extending through 2027, aims to leverage Immunai’s advanced AI platform to analyze extensive patient data for potential therapeutic insights.The collaboration seeks to integrate research on cancer and autoimmune diseases, which are often studied in isolation
A test tube with a colorful chemical compound in a dimly lit lab

Jun 25, 2026

[BIO USA 2026] NVIDIA pushes agentic AI beyond coding and into drug discovery

NVIDIA is advancing its efforts in life sciences through the introduction of agentic AI, which aims to automate complex scientific workflows and enhance drug discovery processes.At the BIO USA 2026 event in San Diego, NVIDIA's Vice President of Healthcare, Kimberly Powell, discussed how AI has evolved from merely assisting researchers with data retrieval to performing tasks autonomously. This shift towards agentic AI signifies a move from generating information to executing multi-step scientific
Close-up of healthy hair follicles on a scalp in a clinical setting

Jun 24, 2026

Eli Lilly dives into hair loss treatments with investment in AI startup Absci

Eli Lilly is taking a strategic step into the hair loss treatment market by investing in the AI-driven startup Absci, which focuses on developing innovative medications for hair growth and possibly endometriosis.Absci recently secured $100 million in funding, with Eli Lilly contributing $40 million as part of the investment round. This move aligns with Lilly's broader strategy to diversify its portfolio beyond its successful weight loss drugs, Wegovy and Mounjaro, into other aesthetic and therap
Minimalist representation of an antibody and small molecule in a dark palette

Jun 24, 2026

The biotech bi-weekly: partnerships facilitating antibody discovery and AI drug development

The past two weeks have seen a surge in partnerships aimed at enhancing drug discovery, particularly in the realm of antibody development and small-molecule therapeutics.Notably, ChemDiv has made strides with its drug discovery platform focused on the central nervous system, facilitating the design of small molecules capable of penetrating the brain. This advancement supports both preclinical and clinical progress for its collaborators, illustrating the platform's potential in addressing neurolo
A laboratory vial with a drug compound in a dimly lit lab setting.

Jun 24, 2026

AI Drug Discovery Boosts Life Sciences Stock

The integration of artificial intelligence (AI) is significantly transforming the life sciences sector, particularly in drug discovery and development.AI technologies are enhancing the efficiency of research within pharmaceutical and biotechnology firms by leveraging advanced data analytics and predictive modeling. This evolution is particularly beneficial for companies with proprietary datasets, as AI tools enable them to extract greater value from existing resources. Notably, AI accelerates dr
A test tube with a bubbling chemical solution on a laboratory bench

Jun 24, 2026

Lilly Expands AI Drug Discovery Push With ‘App Store’ Model For Biotech Scientists

Eli Lilly is leveraging profits from its successful weight-loss and diabetes treatments to enhance its artificial intelligence initiatives, introducing a data-sharing platform for biotech researchers, likened to an "App Store" for scientists by CEO David Ricks. This move is part of a strategic diversification ahead of impending patent expirations for its key drugs in the 2030s.Lilly is heavily investing in AI infrastructure and collaborations to streamline drug discovery. The newly launched Lill
A minimalist illustration of a neuron and molecule in a dark palette.

Jun 24, 2026

Insilico Medicine, SK Biopharmaceuticals Sign Up to $2.5B AI Drug Discovery Pact for Neuroimmune Disorders

Insilico Medicine and SK Biopharmaceuticals have entered a significant collaboration worth up to $2.5 billion aimed at advancing AI-driven drug discovery for neuroimmune disorders.The partnership, announced at the BIO 2026 International Convention, will leverage Insilico's Pharma.AI platform to identify drug targets, optimize molecules, and enhance preclinical drug discovery specifically for conditions affecting the central nervous system (CNS). This initiative addresses critical unmet medical n
A pill bottle and prescription pad on a wooden desk in a clinical office

Jun 24, 2026

[Bio USA] SK Biopharmaceuticals doubles down on AI, open innovation

SK Biopharmaceuticals is prioritizing artificial intelligence and open innovation as key strategies for future growth, particularly in drug discovery.During a recent press conference at the BIO International Convention in San Diego, CEO Lee Dong-hoon highlighted the company's commitment to leveraging AI technologies alongside traditional development methods. This shift comes on the heels of the successful launch of Xcopri, a seizure medication that has significantly boosted the company's revenue
A molecular model on a lab bench in a modern laboratory setting.

Jun 23, 2026

Genesis Workbench: A blueprint for industry AI in life sciences, powered by Databricks and NVIDIA

The Genesis Workbench represents a significant advancement in AI-driven drug discovery, integrating NVIDIA's accelerated computing with Databricks' robust data governance.This innovative platform offers a comprehensive solution for life sciences research by unifying various stages of drug discovery into a single, modular workbench. It leverages NVIDIA's BioNeMo models and the Databricks environment, allowing scientists to run AI applications directly on their sensitive data without needing to se
Minimalist illustration of a DNA helix and data flow

Jun 23, 2026

Snowflake and NVIDIA Bring Agentic AI to Life Sciences

Snowflake and NVIDIA have partnered to introduce agentic AI to the life sciences sector, enhancing the efficiency of research and development workflows.This collaboration leverages Snowflake’s data governance and orchestration capabilities alongside NVIDIA’s BioNeMo Agent Toolkit, which includes specialized AI models tailored for biological research. The integration allows pharmaceutical R&D teams to conduct complex scientific workflows directly where their data resides, thereby accelerating the
A drug compound in a petri dish in a dimly lit lab

Jun 23, 2026

The Next Frontier: AI Agents in Biology

NVIDIA's BioNeMo Agent Toolkit is poised to revolutionize drug discovery by integrating advanced AI capabilities into the life sciences sector, addressing longstanding inefficiencies in research and development.The toolkit has quickly gained traction among over 50 organizations, including major pharmaceutical companies, highlighting its importance in the biotech landscape. By leveraging agentic AI, which autonomously executes complex scientific workflows, BioNeMo aims to mitigate the high costs